Injection site reactions Injection site reactions represent the second major category of adverse events with cagrilintide, and this is where the compound differs most dramatically from GLP-1 medications
While overdosing through food sources is nearly impossible, taking large doses via supplements or IV therapy can carry some risks
GLP-1 medications slow gastric emptying and affect gut motility, which can cause nausea, diarrhoea, constipation, and bloating
Liquid formulations also tend to have shorter shelf lives once opened, as the peptide in solution is more susceptible to degradation than in solid form
[51:32] So what things are you finding most helpful
Animal data covers relatively short treatment cycles, and extrapolating beyond that requires clinical judgment